BRAF and bladder transitional cell carcinoma: Studies using a range of molecular technologies, from whole-exome sequencing to PCR of exon 15 of BRAF to droplet digital PCR of specific nucleotides in BRAF, have reported the BRAF p.V595E mutation in 40–87% of canine urinary bladder urothelial carcinoma (UC) and 60–85% of canine prostate carcinoma (PC) [29,30,31,32,33,34,35,36].